Acquired L1196M <i>ALK</i> mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration-Reference-Cited by-同舟云学术

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration

Published:2023-01-24 Issue:1 Volume:4 Page:305-308
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Noguchi Kazuhiro¹^ORCID,Ikawa Yasuhiro¹^ORCID,Takenaka Mika¹,Sakai Yuta¹,Fujiki Toshihiro¹^ORCID,Kuroda Rie¹,Ikeda Hiroko²,Abe Takatoshi³,Sakai Seisho³,Wada Taizo¹

Affiliation:

1. Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan

2. Department of Diagnostic Pathology Kanazawa University Hospital Kanazawa Japan

3. Department of Pediatric Surgery Kanazawa University Hospital Kanazawa Japan

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.646

Reference12 articles.

1. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

2. Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation

3. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma

4. CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

5. Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report;Precision Oncogenomics;2024-08-12

3. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review;Cancers;2023-12-07

4. Antineoplastics;Reactions Weekly;2023-04-22